<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">21732930</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>08</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>08</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1365-2141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>154</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2011</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>British journal of haematology</Title>
<ISOAbbreviation>Br. J. Haematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.</ArticleTitle>
<Pagination>
<MedlinePgn>755-62</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2141.2011.08791.x</ELocationID>
<Abstract>
<AbstractText>Novel therapies have transformed the treatment paradigm for multiple myeloma with significant improvements in survival now seen in both younger and older patients. Nonetheless, the disease is heterogeneous and high-risk patients in particular continue to have poor outcome. Moreover, the disease remains incurable. Efforts to refine risk stratification and disease characteristics continue with the use of cytogenetics, enhanced imaging techniques and other new technologies, such as genomics. The integration of novel therapies into induction therapy, consolidation and maintenance continues to evolve, and the appropriate use of combination strategies including proteasome inhibition and immunomodulatory treatment is emerging as a platform with application across the disease spectrum. Despite these advances, resistance to novel agents occurs and so the identification of new targets and the recognition of clonal heterogeneity are especially important as improvements to current treatment strategies are developed, with the goal of further improving patient outcome. </AbstractText>
<CopyrightInformation>Â© 2011 Blackwell Publishing Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Richardson</LastName>
<ForeName>Paul G</ForeName>
<Initials>PG</Initials>
<AffiliationInfo>
<Affiliation>Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School Boston, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Laubach</LastName>
<ForeName>Jacob</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mitsiades</LastName>
<ForeName>Constantine S</ForeName>
<Initials>CS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schlossman</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hideshima</LastName>
<ForeName>Teru</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Redman</LastName>
<ForeName>Katherine</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chauhan</LastName>
<ForeName>Dharminder</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ghobrial</LastName>
<ForeName>Irene M</ForeName>
<Initials>IM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Munshi</LastName>
<ForeName>Nikhil</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Anderson</LastName>
<ForeName>Kenneth C</ForeName>
<Initials>KC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Haematol</MedlineTA>
<NlmUniqueID>0372544</NlmUniqueID>
<ISSNLinking>0007-1048</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002869">Chromosome Aberrations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">malignancy</Keyword>
<Keyword MajorTopicYN="N">multiple myeloma</Keyword>
<Keyword MajorTopicYN="N">therapies</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>7</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>7</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>8</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21732930</ArticleId>
<ArticleId IdType="doi">10.1111/j.1365-2141.2011.08791.x</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>